Bryce Point Capital LLC Makes New $448,000 Investment in 10x Genomics, Inc. (NASDAQ:TXG)

Bryce Point Capital LLC purchased a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 31,215 shares of the company’s stock, valued at approximately $448,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cerity Partners LLC grew its position in 10x Genomics by 42.3% during the third quarter. Cerity Partners LLC now owns 36,367 shares of the company’s stock worth $821,000 after buying an additional 10,815 shares in the last quarter. Rockefeller Capital Management L.P. grew its holdings in shares of 10x Genomics by 37.2% during the third quarter. Rockefeller Capital Management L.P. now owns 17,504 shares of the company’s stock worth $395,000 after purchasing an additional 4,746 shares in the last quarter. Verition Fund Management LLC increased its position in shares of 10x Genomics by 26.3% in the third quarter. Verition Fund Management LLC now owns 13,860 shares of the company’s stock worth $313,000 after purchasing an additional 2,890 shares during the last quarter. Benjamin Edwards Inc. raised its stake in 10x Genomics by 18,454.8% in the third quarter. Benjamin Edwards Inc. now owns 58,262 shares of the company’s stock valued at $1,315,000 after purchasing an additional 57,948 shares in the last quarter. Finally, HighTower Advisors LLC bought a new stake in 10x Genomics during the third quarter valued at approximately $430,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Leerink Partnrs lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. UBS Group reduced their target price on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Canaccord Genuity Group lowered their price target on 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. JPMorgan Chase & Co. cut their price objective on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Finally, Citigroup reduced their price objective on 10x Genomics from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.21.

Insider Transactions at 10x Genomics

In other news, insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the sale, the insider now owns 335,324 shares of the company’s stock, valued at approximately $3,712,036.68. The trade was a 1.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Alan Mateo purchased 40,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was bought at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the purchase, the director now owns 61,691 shares of the company’s stock, valued at $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 10.03% of the company’s stock.

10x Genomics Stock Down 6.3 %

NASDAQ:TXG opened at $7.47 on Friday. The firm has a market capitalization of $913.60 million, a P/E ratio of -4.91 and a beta of 1.93. 10x Genomics, Inc. has a 52 week low of $7.19 and a 52 week high of $37.74. The company has a fifty day moving average of $11.41 and a 200 day moving average of $14.66.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.